• 52,775+ CME Conference Registrations Sold
  • 158,324+ Medical Conferences
  • 285 Specialties
  • 11,427 Organizers
  • 157,205 Speakers
  • 159 Countries
  • 4,804 Cities
Home  >  Speakers  >  Miro Venturi
Miro Venturi

Miro Venturi

Senior Vice President, Head | Basel, Basel-Stadt    Switzerland
Physiology And Biophysics
Physiology And Biophysics, Healthcare Management,...More
Spoken at 2 events

Biography :

After receiving his PhD from the Max-Planck Institute of Biophysics in Frankfurt, Miro specialized in molecular medicine, virology and immunology at the National Institutes of Health, Bethesda, USA. In 2002, Miro joined the pharmaceutical industry as a Biomarker Laboratory Head and project team representative at Pharmacia Corp (later Pfizer Inc.) at the Oncology R&D site located in Nerviano, Italy.

In this role, he initially established the biomarker laboratories and actively contributed to the development of numerous oncology programs focusing on small molecular weight kinase inhibitors, including the early development of sunitinib (Sutent) as well as research and exploratory biomarker strategies for several preclinical programs, from lead optimization until PoC clinical studies.

In 2005, Miro was invited to join the faculty of the University “Vita Salute San Raffaele” in Milan as Adjunct Professor of preclinical and early clinical development of biopharmaceuticals. In 2007 Miro moved to Novartis as Divisional Head in Biomarker Development, supervising a team of scientists developing assays and supporting project teams in the realization of personalized medicine strategies across the portfolio, with a focus on biologics and oncology programs.

His team has contributed to the development of nilotinib (Tasigna) and early programs in both solid tumors and hematological malignancies. Since 2009, Miro joined Roche Oncology where he has contributed the biomarker and personalized medicine strategies and directed the execution for global drug development programs with companion diagnostics, including the development and approval of Perjeta in breast cancer. Miro has recently been appointed Global Head of Diagnostics Biomarkers at Hoffmann-la Roche and is based at the Company´s headquarters in Basel.

********** ****
For speaker's contact information - Contact us


Physiology and Biophysics

Interested Topics

Physiology and Biophysics, Healthcare Management, Biomarkers, Biochemistry, Clinical Development, Oncology, Drug Development, Drug Discovery, Business Development, Molecular Medicine, Molecular Virology

State Licenses

This section has yet to be updated by the speaker.

Board Certifications

This section has yet to be updated by the speaker.

Professional Association

This section has yet to be updated by the speaker.


This section has yet to be updated by the speaker.

Conference Session Materials

The conference session material has yet to be added by the speaker.

Send Message

Live to Virtual Conference

Market your online event to Million plus Healthcare professionals.